Sarah Glennie

Sarah is the Chief Business Officer and brings over 20 years of immunological expertise focusing on developing immuno-therapeutics across areas of Immune-Oncology, Autoimmunity, Inflammation and Infection. She has worked both as an academic and commercial immunologist recently leading UK and European teams that offer complex preclinical business development service. Sarah has a global reach and perspective across the industry; with a wealth of preclinical and clinical expertise she helps clients navigate their drug discovery programs with speed and agility. Her previous positions include Sr Client Manager at Charles River Laboratories, Business Development KWS Biotest, Research Fellowship position at the University of Bristol.